Zhang et al. [89] performed a systemic literature search of randomized control trials comparing mineralocorticoid receptor antagonists (finerenone), SGLT-2i, and glucagon-like peptide-1 receptor agonists (GLP-1 RA) in diabetics with CKD. This evidence concerns the gene NR3C2 and chronic kidney disease.